An Epidemiological Study of Acute Coronary Syndromes in The Greek Population
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 418
- 试验地点
- 1
- 主要终点
- To evaluate the proportion of patients who are on target for LDL-C according to the 2004-updated NCEP ATPIII guidelines as calculated within the first 24-hours of hospital admission for an ACS.
研究概览
简要总结
This is a multicenter, 2-phase observational study of acute coronary syndromes (ACS) in Greece, designed to provide real world data on the risk factors of patients presenting to a hospital emergency department with an index event, as well as to depict the current management practices and outcomes of these clinical conditions in Greece.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of an ACS (STEMI, NSTEMI, UA).
- •Informed Consent
排除标准
- •Involvement in the planning and conduct of the study (applies to both AstraZeneca staff and staff at the study sites).
- •Participation in other clinical study in period between the index event and 6- month follow-up assessment with the exception of registering in registries or surveys not influencing the management of the ACS.
结局指标
主要结局
To evaluate the proportion of patients who are on target for LDL-C according to the 2004-updated NCEP ATPIII guidelines as calculated within the first 24-hours of hospital admission for an ACS.
时间窗: first visit - 1st day (cross-sectional part)
To estimate the proportion of patients enrolled in the cross-sectional part of the study that experiences a Major Adverse Cardiovascular Event (MACE) within a 6-month follow-up period.
时间窗: follow up visit - 6th month (prospective part)
次要结局
- To estimate the proportion of patients admitted to the hospital with STEMI, NSTEMI and unstable angina.(first visit - 1st day (cross-sectional part))
- To estimate the "pain-to-door-time" throughout different regions in Greece.(first visit - 1st day (cross-sectional part))
- To estimate the time to first MACE and to estimate CV, non-CV and all cause mortality within the 6-month period following the index ACS event.(follow up visit - 6th month (prospective part))